Casdatifan
- Generic Name
- Casdatifan
Sylvester Comprehensive Cancer Center to Present Groundbreaking Research at ASCO 2025 Annual Meeting
• Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.
• Highlighted studies include the ADVANCE clinical trial examining novel multiple myeloma treatments, innovative virtual reality interventions for stem cell transplant patients, and groundbreaking research on alcohol-related cancer mortality in the US.
• The extensive research portfolio demonstrates Sylvester's leadership in developing cutting-edge cancer therapies, addressing health disparities, and improving supportive care for diverse patient populations.
Arcus's HIF-2α Inhibitor Shows Promise in Kidney Cancer, Despite Gilead's Exit
• Arcus Biosciences' casdatifan demonstrates superior efficacy profile compared to Merck's Welireg in Phase I/Ib kidney cancer trial, showcasing potential advancement in HIF-2α inhibition.
• Gilead Sciences opts not to exercise its option rights for casdatifan development, marking a significant shift in the long-standing partnership with Arcus.
• The promising Phase I/Ib results suggest casdatifan could represent a new therapeutic option for kidney cancer patients, pending further clinical development.
Arcus Biosciences to Present Casdatifan Monotherapy Data in Advanced Kidney Cancer at ASCO GU 2025
• Arcus Biosciences will showcase safety and efficacy data from the ARC-20 study evaluating casdatifan in previously treated kidney cancer patients at the 2025 ASCO GU Symposium.
• The presentation will feature initial results from the 100mg QD tablet cohort, which represents the selected dose for upcoming Phase 3 studies.
• Updated data from the 50mg BID and 50mg QD expansion cohorts will provide additional insights into casdatifan's performance in patients who received prior TKI and anti-PD-1 therapy.
Novel HIF-2α Inhibitor Casdatifan Shows Promise in Advanced Kidney Cancer Phase 1 Trial
• Dana-Farber researchers report casdatifan, a novel HIF-2α inhibitor, demonstrates promising clinical activity and tolerability in heavily pretreated clear cell renal cell carcinoma patients.
• Blood-based KIM-1 biomarker identified as potential early indicator of immunotherapy response in advanced kidney cancer, offering new monitoring possibilities.
• Final follow-up data from CheckMate9ER trial confirms long-term benefits of nivolumab-cabozantinib combination therapy in advanced renal cell carcinoma patients.
Gastrointestinal Cancer Symposium 2025: Key Advances in Treatment Strategies
• Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.
• Encorafenib combined with cetuximab and chemotherapy shows significant improvement in overall response rate for BRAF V600E-mutated metastatic colorectal cancer.
• TACE plus camrelizumab and rivoceranib extends progression-free survival in patients with unresectable hepatocellular carcinoma, offering a manageable safety profile.
Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements
• Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.
• A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months.
• Bio-Path Holdings reported a meaningful patient response in a Phase 1/1b trial of BP1002 for refractory/relapsed AML, with stable disease and reduced blast count after one treatment cycle.
• Bio-Path Holdings' BP1001-A demonstrated continued tumor reduction and stable disease in a solid tumor patient, alongside durable remissions in AML patients treated with prexigebersen.
Arcus Biosciences and AstraZeneca Collaborate to Evaluate Novel Combination Therapy for Clear Cell Renal Cell Carcinoma
• Arcus Biosciences and AstraZeneca are collaborating to evaluate casdatifan, a HIF-2a inhibitor, with volrustomig, a PD-1/CTLA-4 bispecific antibody, for ccRCC treatment.
• AstraZeneca will sponsor a clinical trial to assess the safety and early efficacy of the casdatifan and volrustomig combination in patients with advanced ccRCC.
• This collaboration marks the second between Arcus and AstraZeneca, building on their previous work in non-small cell lung cancer with domvanalimab and durvalumab.
• The combination aims to improve outcomes for ccRCC patients by leveraging HIF-2a inhibition and PD-1/CTLA-4 blockade to drive deeper and more durable responses.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath